Antimicrobial peptide production in response to gut microbiota imbalance

Peptides. 2022 Nov:157:170865. doi: 10.1016/j.peptides.2022.170865. Epub 2022 Aug 28.

Abstract

The gut microbiota presents essential functions in the immune response. The gut epithelium acts as a protective barrier and, therefore, can produce several antimicrobial peptides (AMPs) that can act against pathogenic microorganisms, including bacteria. Several factors cause a disturbance in gut microbiota, including the exacerbated and erroneous use of antibiotics. Antibiotic therapy has been closely related to bacterial resistance and is also correlated with undesired side-effects to the host, including the eradication of commensal bacteria. Consequently, this results in gut microbiota imbalance and inflammatory bowel diseases (IBD) development. In this context, AMPs in the gut epithelium play a restructuring role for gut microbiota. Some naturally occurring AMPs are selective for pathogenic bacteria, thus preserving the health microbiota. Therefore, AMPs produced by the host's epithelial cells represent effective molecules in treating gut bacterial infections. Bearing this in mind, this review focused on describing the importance of the host's AMPs in gut microbiota modulation and their role as anti-infective agents against pathogenic bacteria.

Keywords: Antimicrobial peptides; Bacteria; Gut barrier; Gut epithelium; Microbiota.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Bacterial Agents / pharmacology
  • Anti-Bacterial Agents / therapeutic use
  • Anti-Infective Agents*
  • Antimicrobial Peptides
  • Bacteria
  • Bacterial Infections*
  • Gastrointestinal Microbiome*
  • Humans

Substances

  • Anti-Bacterial Agents
  • Anti-Infective Agents
  • Antimicrobial Peptides